CY1124316T1 - Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα - Google Patents
Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματαInfo
- Publication number
- CY1124316T1 CY1124316T1 CY20211100652T CY211100652T CY1124316T1 CY 1124316 T1 CY1124316 T1 CY 1124316T1 CY 20211100652 T CY20211100652 T CY 20211100652T CY 211100652 T CY211100652 T CY 211100652T CY 1124316 T1 CY1124316 T1 CY 1124316T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical preparations
- pi3k delta
- selective inhibitor
- tosylate salt
- crystalline tosylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2596CH2014 | 2014-05-27 | ||
| IN2597CH2014 | 2014-05-27 | ||
| PCT/IB2015/053940 WO2015181728A1 (en) | 2014-05-27 | 2015-05-26 | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124316T1 true CY1124316T1 (el) | 2022-07-22 |
Family
ID=53499042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100652T CY1124316T1 (el) | 2014-05-27 | 2021-07-21 | Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9969740B2 (enExample) |
| EP (2) | EP3971188A1 (enExample) |
| JP (3) | JP6987501B2 (enExample) |
| KR (1) | KR20170007480A (enExample) |
| CN (2) | CN106661030B (enExample) |
| AU (1) | AU2015265542B2 (enExample) |
| BR (1) | BR112016027674A2 (enExample) |
| CA (1) | CA2949932C (enExample) |
| CY (1) | CY1124316T1 (enExample) |
| DK (1) | DK3149000T3 (enExample) |
| EA (1) | EA032506B1 (enExample) |
| ES (1) | ES2880999T3 (enExample) |
| HR (1) | HRP20211151T1 (enExample) |
| HU (1) | HUE054916T2 (enExample) |
| IL (1) | IL249058B2 (enExample) |
| LT (1) | LT3149000T (enExample) |
| PL (1) | PL3149000T3 (enExample) |
| PT (1) | PT3149000T (enExample) |
| RS (1) | RS62136B1 (enExample) |
| SI (1) | SI3149000T1 (enExample) |
| SM (1) | SMT202100532T1 (enExample) |
| WO (1) | WO2015181728A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3149000T (pt) * | 2014-05-27 | 2021-07-27 | Rhizen Pharmaceuticals S A | Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas |
| CA3024123A1 (en) | 2016-05-27 | 2017-11-30 | Tg Therapeutics, Inc. | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |
| BR112019004185A2 (pt) | 2016-09-09 | 2019-09-03 | Lab Francais Du Fractionnement | combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos |
| CA3146785A1 (en) * | 2019-07-15 | 2021-01-21 | Johnson Matthey Public Limited Company | Amorphous umbralisib monotosylate |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1278748B1 (en) | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| US20100202963A1 (en) | 2008-11-13 | 2010-08-12 | Gallatin W Michael | Therapies for hematologic malignancies |
| CN102439012A (zh) | 2009-03-24 | 2012-05-02 | 吉里德卡利斯托加公司 | 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法 |
| CA2759724A1 (en) | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals, Inc. | Methods of treatment for solid tumors |
| JP6181173B2 (ja) * | 2012-07-04 | 2017-08-16 | ライゼン・ファーマシューティカルズ・エスアー | 選択的ｐｉ３ｋデルタ阻害剤 |
| PT3149000T (pt) * | 2014-05-27 | 2021-07-27 | Rhizen Pharmaceuticals S A | Sal tosilato cristalino de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas |
-
2015
- 2015-05-26 PT PT157335324T patent/PT3149000T/pt unknown
- 2015-05-26 RS RS20210920A patent/RS62136B1/sr unknown
- 2015-05-26 US US15/313,454 patent/US9969740B2/en active Active
- 2015-05-26 EP EP21182208.5A patent/EP3971188A1/en not_active Withdrawn
- 2015-05-26 AU AU2015265542A patent/AU2015265542B2/en not_active Ceased
- 2015-05-26 SI SI201531656T patent/SI3149000T1/sl unknown
- 2015-05-26 EA EA201692255A patent/EA032506B1/ru unknown
- 2015-05-26 KR KR1020167036318A patent/KR20170007480A/ko not_active Ceased
- 2015-05-26 WO PCT/IB2015/053940 patent/WO2015181728A1/en not_active Ceased
- 2015-05-26 CN CN201580034288.7A patent/CN106661030B/zh not_active Expired - Fee Related
- 2015-05-26 ES ES15733532T patent/ES2880999T3/es active Active
- 2015-05-26 DK DK15733532.4T patent/DK3149000T3/da active
- 2015-05-26 HR HRP20211151TT patent/HRP20211151T1/hr unknown
- 2015-05-26 SM SM20210532T patent/SMT202100532T1/it unknown
- 2015-05-26 PL PL15733532T patent/PL3149000T3/pl unknown
- 2015-05-26 LT LTEPPCT/IB2015/053940T patent/LT3149000T/lt unknown
- 2015-05-26 CN CN202010471226.5A patent/CN111635406A/zh active Pending
- 2015-05-26 JP JP2016569636A patent/JP6987501B2/ja not_active Expired - Fee Related
- 2015-05-26 CA CA2949932A patent/CA2949932C/en active Active
- 2015-05-26 BR BR112016027674A patent/BR112016027674A2/pt not_active Application Discontinuation
- 2015-05-26 HU HUE15733532A patent/HUE054916T2/hu unknown
- 2015-05-26 EP EP15733532.4A patent/EP3149000B1/en active Active
-
2016
- 2016-11-20 IL IL249058A patent/IL249058B2/en unknown
-
2018
- 2018-04-11 US US15/950,606 patent/US10414773B2/en active Active
-
2019
- 2019-08-30 US US16/557,091 patent/US10947244B2/en not_active Expired - Fee Related
-
2020
- 2020-05-20 JP JP2020088147A patent/JP2020122022A/ja active Pending
- 2020-12-23 US US17/247,806 patent/US20210269446A1/en not_active Abandoned
-
2021
- 2021-07-21 CY CY20211100652T patent/CY1124316T1/el unknown
-
2022
- 2022-04-05 JP JP2022062937A patent/JP2022082680A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124316T1 (el) | Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα | |
| CY1121793T1 (el) | Εκλεκτικοι αναστολεις pi3k δελτα | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1119615T1 (el) | Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης | |
| CY1122098T1 (el) | Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3 | |
| CY1120941T1 (el) | Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CY1119391T1 (el) | Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| EA201691484A1 (ru) | Соли и твердая форма ингибитора btk | |
| MX383164B (es) | Composicion que contiene arn para tratamiento de enfermedades tumorales. | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| CL2015002361A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| EA202090291A3 (ru) | Производные бипиразола в качестве ингибиторов jak | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| WO2016100347A3 (en) | Small molecule inhibitors of egfr and pi3k | |
| CY1122763T1 (el) | Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| EA201792689A1 (ru) | Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica |